Previous studies have shown that pyridostigmine (PD) is capable of increasing the growth hormone (GH) response to GH-releasing hormone (GHRH) in young healthy subjects. In order to investigate the influence of age and sex on the PD potentiation of GHRH-induced GH release, we have studied the GH response to GHRH (50-mu-g iv.) 1 h after oral administration of placebo or PD (60 mg) in 8 young healthy men (aged 19-28 years) and 8 age-matched young women (aged 18-25 years) during the follicular phase of the menstrual cycle, as well as in 8 postmenopausal women (aged 57-62 years) and 8 age-matched elderly men (aged 56-64 years). In the same subjects the effect of PD alone (60 mg p.o.) was also studied. Furthermore, in 6 postmenopausal women and 6 elderly men, the effect of a 30-mg PD oral dose on GH secretion and GH response to GHRH was evaluated with a similar protocol. The GH responses (mean +/- SE) to GHRH + placebo were similar in young men (peak 20.1 +/- 2 ng/ml, AUC 1,250 +/- 113 ng/ml/min) and women (peak 29.3 +/- 2.3 ng/ml, AUC 1,769 +/- 305 ng/ml/min). PD 60 mg was capable of significantly increasing the GH response to GHRH in young men (peak 43.5 +/- 5.1 ng/ml, AUC 3,734 +/- 472 ng/ml/min, p < 0.005) but not in women (peak 39 +/- 2.3 ng/ml, AUC 2,479 +/- 205 ng/ml/min). The GH responses to GHRH + placebo were also similar in postmenopausal women (peak 6.2 +/- 0.7 ng/ml, AUC 540 +/- 80 ng/ml/min) and age-matched men (peak 11.3 +/- 0.6 ng/ml, AUC 763 +/- 73 ng/ml/min) although these responses were significantly decreased when compared to those observed in young individuals. PD 60 mg administration induced a significant increase in GH response to GHRH both in postmenopausal women (peak 27 +/- 3.6 ng/ml, AUC 2,224 +/- 251 ng/ml/min, p < 0.001) and elderly men (peak 49.7 +/- 2.4 ng/ml, AUC 4,557 +/- 263 ng/ml/min, p < 0.001). The GH increment, however, was greater in elderly men than in postmenopausal women (p < 0.005). In young men, elderly men and postmenopausal women, PD 60 mg potentiated the action of GHRH rather than merely being additive. A similar effect was observed when a 30-mg PD dose was preadministered in elderly men and women. Our data clearly demonstrate a marked influence of age and sex on the PD potentiation of the GHRH-stimulated GH secretion. PD significantly potentiated GH responses to GHRH in young men, elderly men and postmenopausal women but not in young women.

EFFECTS OF SEX AND AGE ON PYRIDOSTIGMINE POTENTIATION OF GROWTH HORMONE-RELEASING HORMONE-INDUCED GROWTH-HORMONE RELEASE

CORSELLO S;
1992-01-01

Abstract

Previous studies have shown that pyridostigmine (PD) is capable of increasing the growth hormone (GH) response to GH-releasing hormone (GHRH) in young healthy subjects. In order to investigate the influence of age and sex on the PD potentiation of GHRH-induced GH release, we have studied the GH response to GHRH (50-mu-g iv.) 1 h after oral administration of placebo or PD (60 mg) in 8 young healthy men (aged 19-28 years) and 8 age-matched young women (aged 18-25 years) during the follicular phase of the menstrual cycle, as well as in 8 postmenopausal women (aged 57-62 years) and 8 age-matched elderly men (aged 56-64 years). In the same subjects the effect of PD alone (60 mg p.o.) was also studied. Furthermore, in 6 postmenopausal women and 6 elderly men, the effect of a 30-mg PD oral dose on GH secretion and GH response to GHRH was evaluated with a similar protocol. The GH responses (mean +/- SE) to GHRH + placebo were similar in young men (peak 20.1 +/- 2 ng/ml, AUC 1,250 +/- 113 ng/ml/min) and women (peak 29.3 +/- 2.3 ng/ml, AUC 1,769 +/- 305 ng/ml/min). PD 60 mg was capable of significantly increasing the GH response to GHRH in young men (peak 43.5 +/- 5.1 ng/ml, AUC 3,734 +/- 472 ng/ml/min, p < 0.005) but not in women (peak 39 +/- 2.3 ng/ml, AUC 2,479 +/- 205 ng/ml/min). The GH responses to GHRH + placebo were also similar in postmenopausal women (peak 6.2 +/- 0.7 ng/ml, AUC 540 +/- 80 ng/ml/min) and age-matched men (peak 11.3 +/- 0.6 ng/ml, AUC 763 +/- 73 ng/ml/min) although these responses were significantly decreased when compared to those observed in young individuals. PD 60 mg administration induced a significant increase in GH response to GHRH both in postmenopausal women (peak 27 +/- 3.6 ng/ml, AUC 2,224 +/- 251 ng/ml/min, p < 0.001) and elderly men (peak 49.7 +/- 2.4 ng/ml, AUC 4,557 +/- 263 ng/ml/min, p < 0.001). The GH increment, however, was greater in elderly men than in postmenopausal women (p < 0.005). In young men, elderly men and postmenopausal women, PD 60 mg potentiated the action of GHRH rather than merely being additive. A similar effect was observed when a 30-mg PD dose was preadministered in elderly men and women. Our data clearly demonstrate a marked influence of age and sex on the PD potentiation of the GHRH-stimulated GH secretion. PD significantly potentiated GH responses to GHRH in young men, elderly men and postmenopausal women but not in young women.
1992
PYRIDOSTIGMINE
gh
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.14245/920
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 7
social impact